Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Reviewing Omega Therapeutics (NASDAQ:OMGA) and ERYTECH Pharma (NASDAQ:ERYP)

Defense World ·  {{timeTz}}

ERYTECH Pharma (NASDAQ:ERYP – Get Rating) and Omega Therapeutics (NASDAQ:OMGA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

4.9% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 88.8% of Omega Therapeutics shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by insiders. Comparatively, 60.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Get ERYTECH Pharma alerts:

Profitability

This table compares ERYTECH Pharma and Omega Therapeutics' net margins, return on equity and return on assets .

Net Margins Return on Equity Return on Assets
ERYTECH Pharma N/A N/A N/A
Omega Therapeutics N/A -44.99% -38.54%

Valuation and Earnings

This table compares ERYTECH Pharma and Omega Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ERYTECH Pharma $4.95 million 5.39 -$63.65 million N/A N/A
Omega Therapeutics $140,000.00 1,678.27 -$68.28 million ($1.97) -2.49

ERYTECH Pharma has higher revenue and earnings than Omega Therapeutics.

Analyst Ratings

This is a summary of current ratings and price targets for ERYTECH Pharma and Omega Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ERYTECH Pharma 0 3 0 0 2.00
Omega Therapeutics 0 1 1 0 2.50

Omega Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 22.20%. Given Omega Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Omega Therapeutics is more favorable than ERYTECH Pharma.

Summary

Omega Therapeutics beats ERYTECH Pharma on 6 of the 10 factors compared between the two stocks .

About ERYTECH Pharma

(Get Rating)

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

About Omega Therapeutics

(Get Rating)

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for ERYTECH Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ERYTECH Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.